Sarah Lauks

Sarah Lauks

Auto-generated profile, based on publicly available information

Sarah Lauks

Department of Neurology with Institute of Translational Neurology, University Hospital of Münster, University of Münster, 48149 Münster, Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2024 in Science Translational Medicine
Verified
Journal Article
Closed access
CGCatharina C. Gross
Catharina C. Gross
ASAndreas Schulte-Mecklenbeck
Andreas Schulte-Mecklenbeck
OSOlga V. Steinberg
Olga V. Steinberg
TWTimo Wirth
Timo Wirth
SLSarah Lauks
Sarah Lauks
MWMartin S. Weber
Martin S. Weber
One of the biggest challenges in managing multiple sclerosis is the heterogeneity of clinical manifestations and progression trajectories. It still remains to be elucidated whether this heterogeneity is reflected by discrete immune signatures in the blood as a surrogate of disease pathophysiology. Accordingly, individualized treatment selection based on immunobiological principles is still not feasible. Using two independent multicentric longitudinal cohorts of patients with early multiple sclerosis ( n = 309 discovery and n = 232 validation), we were able to identify three distinct peripheral blood immunological endophenotypes by a combination of high-dimensional flow cytometry and serum proteomics, followed by unsupervised clustering. Longitudinal clinical and paraclinical follow-up data collected for the cohorts revealed that these endophenotypes were associated with disease trajectories of inflammation versus early structural damage. Investigating the capacity of immunotherapies to normalize endophenotype-specific immune signatures revealed discrete effect sizes as illustrated by the limited effect of interferon-β on endophenotype 3–related immune signatures. Accordingly, patients who fell into endophenotype 3 subsequently treated with interferon-β exhibited higher disease progression and MRI activity over a 4-year follow-up compared with treatment with other therapies. We therefore propose that ascertaining a patient’s blood immune signature before immunomodulatory treatment initiation may facilitate prediction of clinical disease trajectories and enable personalized treatment decisions based on pathobiological principles.

25 April 2023 in Neurology
Verified
Journal Article
Closed access
CGCatharina C. Gross
Catharina C. Gross
ASAndreas Schulte-Mecklenbeck
Andreas Schulte-Mecklenbeck
OSOlga V. Steinberg
Olga V. Steinberg
TWTimo Wirth
Timo Wirth
SLSarah Lauks
Sarah Lauks
HWHeinz Wiendl
Heinz Wiendl
Objective: To identify immune-response signatures in the blood of multiple sclerosis (MS) patients predictive for clinical disease trajectories and supporting personalized treatment decisions based on pathobiological principles. Background: MS is a neuro-immunological disease representing with a broad spectrum of clinical manifestations and disease progression. To date it is still controversially discussed, whether discrete immune-response signatures in the blood represent inflammatory disease characteristics versus signs of early neurodegeneration with prognostic and therapeutic consequences. Design/Methods: In this multicentric prospective study, we employed high-dimensional flow cytometry and targeted proteomics to a discovery cohort of 378 treatment-naïve early (£ 2years from disease onset) MS patients from the NationMS cohort with comprehensive clinical and paraclinical data. Resulting data were analyzed applying state-of-the-art computational biology. Results were reproduced in a validation cohort of 78 MS patients. Results: We identified MS as a disease of disturbed immune-regulatory networks that can be detected in the blood. Early MS consists of four immunological endophenotypes associated with different HLA-backgrounds suggestive for discrete immunological pathways in disease pathogenesis. Immunological endophenotypes were mirrored by specific clinical and paraclinical disease trajectories exhibiting inflammatory disease characteristics versus signs of early neurodegeneration. Distinct immune-therapeutic principles differed in their capacity to normalize immune-response signatures associated with each endophenotype, exemplified by the limited effect of interferon-beta on immune-response signatures in patients with the inflammatory endophenotype, which was accompanied by increased clinical and imaging features of diseases progression in these patients. Conclusions: Ascertaining immune-response signatures in the blood of MS patients is an innovative clinical tool for predicting longitudinal outcomes and guiding personalized treatment decisions based on pathobiological principles. Disclosure: The institution of Catharina Groß has received research support from Biogen. The institution of Catharina Groß has received research support from Roche. Andreas Schulte-Mecklenbeck has nothing to disclose. Mrs. Steinberg has nothing to disclose. Timo Wirth has nothing to disclose. Dr. Lauks has nothing to disclose. Sergio Baranzini has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck Serono. Sergio Baranzini has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Sergio Baranzini has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Aventis. Sergio Baranzini has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nexilico. Sergio Baranzini has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono . Sergio Baranzini has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD SErono. Sergio Baranzini has stock in MATE Bioservices. The institution of Sergio Baranzini has received research support from Valhalla Charitable Fund. The institution of Sergio Baranzini has received research support from Genentech Inc. The institution of Sergio Baranzini has received research support from Salah Foundation. Stefan Bittner has received personal compensation in the range of $500-$4,999 for serving as a Honoria with Biogen Idec. Stefan Bittner has received personal compensation in the range of $500-$4,999 for serving as a Honoria with Merck Healthcare. Stefan Bittner has received personal compensation in the range of $500-$4,999 for serving as a Honoria with Novartis. Stefan Bittner has received personal compensation in the range of $500-$4,999 for serving as a Honoria with Roche. Stefan Bittner has received personal compensation in the range of $500-$4,999 for serving as a Honoria with Sanofi. Stefan Bittner has received personal compensation in the range of $500-$4,999 for serving as a Honoria with Bristol-Meyer-Squibbs. Stefan Bittner has received personal compensation in the range of $500-$4,999 for serving as a Honoria with Teva. Judith Bellmann-Strobl, MD has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Judith Bellmann-Strobl, MD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Judith Bellmann-Strobl, MD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Judith Bellmann-Strobl, MD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. The institution of Judith Bellmann-Strobl, MD has received research support from Bayer. The institution of Judith Bellmann-Strobl, MD has received research support from NEMOS. Dr. Buenger has nothing to disclose. Dr. Eilers has nothing to disclose. Maria Eveslage has nothing to disclose. Dr. Fleischer has nothing to disclose. Dr. Gisevius has nothing to disclose. Sergiu Groppa has nothing to disclose. Juergen Haas has nothing to disclose. Prof. Kerschensteiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Prof. Kerschensteiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Aventis. Prof. Kerschensteiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety...